Department of Physiology, New York Medical College, Valhalla, NY, USA.
Br J Pharmacol. 2011 Jul;163(5):1059-68. doi: 10.1111/j.1476-5381.2011.01307.x.
Antagonists of angiotensin AT(1) receptors elicit beneficial vascular effects in diabetes mellitus. We hypothesized that diabetes induces sustained availability of AT(1) receptors, causing enhanced arterial constriction to angiotensin II.
To assess functional availability of AT(1) receptors, constrictions to successive applications of angiotensin II were measured in isolated skeletal muscle resistance arteries (∼150 µm) of Zucker diabetic fatty (ZDF) rats and of their controls (+/Fa), exposed acutely to high glucose concentrations (HG, 25 mM, 1 h). AT(1) receptors on cell membrane surface were measured by immunofluorescence.
Angiotensin II-induced constrictions to first applications were greater in arteries of ZDF rats (maximum: 82 ± 3% original diameter) than in those from +/Fa rats (61 ± 5%). Constrictions to repeated angiotensin II administration were decreased in +/Fa arteries (20 ± 6%), but were maintained in ZDF arteries (67 ± 4%) and in +/Fa arteries vessels exposed to HG (65 ± 6%). In ZDF arteries and in HG-exposed +/Fa arteries, Rho-kinase activities were enhanced. The Rho-kinase inhibitor, Y27632 inhibited sustained constrictions to angiotensin II in ZDF arteries and in +/Fa arteries exposed to HG. Levels of surface AT(1) receptors on cultured vascular smooth muscle cells (VSMCs) were decreased by angiotensin II but were maintained in VSMCs exposed to HG. In VSMCs exposed to HG and treated with Y27632, angiotensin II decreased surface AT(1) receptors.
In diabetes, elevated glucose concentrations activate Rho-kinase which inhibits internalization or facilitates recycling of AT(1) receptors, leading to increased functional availability of AT(1) receptors and sustained angiotensin II-induced arterial constriction.
血管紧张素 AT(1) 受体拮抗剂在糖尿病中产生有益的血管效应。我们假设糖尿病会导致 AT(1) 受体持续可用性增加,从而导致血管对血管紧张素 II 的收缩增强。
为了评估 AT(1) 受体的功能可用性,我们在 Zucker 糖尿病肥胖 (ZDF) 大鼠和其对照组(+/Fa)的分离骨骼肌阻力血管(约 150 µm)中测量了血管紧张素 II 连续应用引起的收缩,这些动物暴露于高葡萄糖浓度(HG,25 mM,1 h)下。通过免疫荧光法测量细胞膜表面的 AT(1) 受体。
ZDF 大鼠的血管中,第一次应用血管紧张素 II 引起的收缩比+/Fa 大鼠(最大:82 ± 3%原始直径)更大。在+/Fa 动脉中,反复给予血管紧张素 II 后引起的收缩减少(20 ± 6%),但在 ZDF 动脉中保持不变(67 ± 4%),在暴露于 HG 的+/Fa 动脉中也保持不变(65 ± 6%)。在 ZDF 动脉和暴露于 HG 的+/Fa 动脉中,Rho- 激酶活性增强。Rho- 激酶抑制剂 Y27632 抑制了 ZDF 动脉和暴露于 HG 的+/Fa 动脉中对血管紧张素 II 的持续收缩。在培养的血管平滑肌细胞(VSMCs)中,血管紧张素 II 降低了表面 AT(1) 受体的水平,但在暴露于 HG 的 VSMCs 中保持不变。在暴露于 HG 并经 Y27632 处理的 VSMCs 中,血管紧张素 II 降低了表面 AT(1) 受体。
在糖尿病中,升高的葡萄糖浓度激活 Rho- 激酶,抑制 AT(1) 受体内化或促进其再循环,导致 AT(1) 受体的功能可用性增加,并导致持续的血管紧张素 II 诱导的动脉收缩。